This section is intended for UK healthcare professionals. If you are a member of the public click here. If you have been prescribed Ninlaro click here.

Why NINLARO?

Oral NINLARO is a novel approach to proteasome inhibition, designed to deliver sustained efficacy in RRMM1,2

NINLARO is the first and only oral PI licensed in combination with Rd for the treatment of adult patients with MM who have received at least 1 prior therapy1

Adding oral NINLARO to Rd:

Oral NINLARO was studied in a broad group of RRMM patients who were treated to progression2

TOURMALINE‑MM1 is the first global, phase III, double‑blind, placebo‑controlled study investigating an oral PI in RRMM patients. The trial compared NINLARO + Rd as part of an all oral regimen versus placebo + Rd in 722 RRMM patients treated with 1-3 prior therapies2

Watch Professor Moreau present the key findings from the TOURMALINE‑MM1 study

Extended treatment can improve outcomes in MM but may be difficult to achieve3-7

A long-term treatment approach in MM should address efficacy, tolerability and patient burden4

Long-term treatment in MM remains a challenge with a number of current therapeutic options.3

TOURMALINE‑MM1 - the first global, phase III, double‑blind, placebo-controlled study investigating an oral PI in RRMM patients2

TOURMALINE‑MM1 enrolled a broad group of RRMM patients who were treated to progression2

The trial compared NINLARO + Rd as part of an all-oral regimen versus placebo + Rd in 722 RRMM patients treated with 1-3 prior therapies1,2

TOURMALINE-MM1 study design

*Stratification: 1 vs 2 or 3 prior therapies; PI exposed vs PI naïve; and International Staging System (ISS) stage I or II vs III1,2

Read more about the TOURMALINE‑MM1 study

Adding oral NINLARO to Rd significantly extends PFS in RRMM patients2

At 14.7 months' median follow-up, oral NINLARO + Rd significantly extended median PFS by approximately 6 months compared with placebo + Rd1,2

Adding NINLARO to Rd delivered a clinically meaningful 35% improvement in PFS vs placebo + Rd (at the primary and final PFS analysis)2

Adapted from NINLARO Summary of Product Characteristics and Moreau et al. 20161,2

Read more about the efficacy of the NINLARO regimen

Oral NINLARO + Rd is generally well-tolerated with manageable side effects2

Adverse events were generally Grade 1 or 2 and were manageable with supportive care2

AEs occurring in ≥5% of patients with a ≥5% difference between oral NINLARO + Rd and placebo + Rd2*

Adapted from Moreau et al. 20162

* At 23 months' median follow-up Represents multiple MedDRA preferred terms

Eye disorders were reported with many different preferred terms but in aggregate, the frequency was 26% in patients in the NINLARO regimen and 16% of patients in the placebo regimen1

Read more about the tolerability of the NINLARO regimen

NINLARO + Rd offers the convenience of all-oral administration1

The usual recommended starting dose of oral NINLARO is one 4 mg capsule taken once a week with lenalidomide and dexamethasone at standard dosing1

NINLARO + Rd 28‑day dosing schedule1

* The recommended starting dose of dexamethasone is 40 mg - each tablet contains 2 mg dexamethasone

Treatment with NINLARO in combination with Rd for longer than 24 cycles should be based on an individual benefit risk assessment1

Read more about the simplicity of the NINLARO regimen

Patient support

Takeda Oncology has developed a range of information and support tools designed for patients prescribed NINLARO

Click here to find out more about the support offered to NINLARO patients